文献速递浆细胞疾病

SAR442085:一种对多发性骨髓瘤具有增强抗肿瘤活性的新型抗CD38抗体

SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma.
PubMed 文献 · Blood · 2022-01-01

该临床前研究比较了新一代抗CD38单克隆抗体SAR442085与达雷妥尤单抗和伊沙妥昔单抗的疗效。SAR442085对FcγRIIa和FcγRIIIa亲和力更高,体外ADCC更强,在huFcgR转基因小鼠中体内抗肿瘤疗效和生存优于对照抗体。结果支持SAR442085在复发/难治性MM中开展I期临床开发。

要点

  • SAR442085对FcγRIIa(CD32a)和FcγRIIIa(CD16a)的亲和力高于达雷妥尤单抗和伊沙妥昔单抗。
  • SAR442085对表达不同CD38密度的MM细胞及原代浆细胞表现出更强的体外ADCC。
  • 在huFcgR转基因小鼠中,SAR442085的NK细胞依赖性体内抗肿瘤疗效和生存优于达雷妥尤单抗和伊沙妥昔单抗。

核心结论

  • SAR442085的临床前疗效优于达雷妥尤单抗和伊沙妥昔单抗,支持其在复发/难治性MM患者中开展I期临床开发。

研究设计与样本

  • 临床前研究,比较SAR442085与达雷妥尤单抗和伊沙妥昔单抗的疗效。
  • 体外实验使用表达不同CD38密度的MM细胞系、MM患者原代浆细胞及MM患者原代骨髓细胞。
  • 体内实验使用表达人Fcγ受体的huFcgR转基因小鼠,肿瘤模型为过表达人CD38的EL4胸腺瘤或VK*MYC骨髓瘤细胞。

主要发现

  • 表面等离子共振和细胞结合实验显示,SAR442085对FcγRIIa(CD32a)和FcγRIIIa(CD16a)的亲和力高于达雷妥尤单抗和伊沙妥昔单抗。
  • SAR442085对表达不同CD38受体密度的MM细胞系及MM患者原代浆细胞的体外ADCC优于对照抗体。
  • 使用表达低亲和力和高亲和力FcγRIIIa(CD16a)-158F/V变体的NK-92细胞确认了SAR442085增强的ADCC。
  • 使用MM患者原代骨髓细胞,SAR442085结合FcγRIIIa的能力增强,导致对原代浆细胞的NK细胞活化和脱颗粒高于现有Fc野生型抗CD38单克隆抗体。
  • 在huFcgR转基因小鼠中,SAR442085对过表达人CD38的EL4胸腺瘤或VK*MYC骨髓瘤细胞的NK细胞依赖性体内抗肿瘤疗效和生存优于达雷妥尤单抗和伊沙妥昔单抗。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anti-CD38 monoclonal antibodies (mAbs) represent a breakthrough in the treatment of multiple myeloma (MM), yet some patients fail to respond or progress quickly with this therapy, highlighting the need for novel approaches. In this study we compared the preclinical efficacy of SAR442085, a next-generation anti-CD38 mAb with enhanced affinity for activating Fcγ receptors (FcγR), with first-generation anti-CD38 mAb daratumumab and isatuximab. In surface plasmon resonance and cellular binding assays, we found that SAR442085 had higher binding affinity than daratumumab and isatuximab for FcγRIIa (CD32a) and FcγRIIIa (CD16a). SAR442085 also exhibited better in vitro antibody-dependent cellular cytotoxicity (ADCC) against a panel of MM cells expressing variable CD38 receptor densities including MM patients' primary plasma cells. The enhanced ADCC of SAR442085 was confirmed using NK-92 cells bearing low and high affinity FcγRIIIa (CD16a)-158F/V variants. Using MM patients' primary bone marrow cells, we confirmed that SAR442085 had an increased ability to engage FcγRIIIa, resulting in higher natural killer (NK) cell activation and degranulation against primary plasma cells than preexisting Fc wild-type anti-CD38 mAbs. Finally, using huFcgR transgenic mice that express human Fcγ receptors under the control of their human regulatory elements, we demonstrated that SAR442085 had higher NK cell-dependent in vivo antitumor efficacy and better survival than daratumumab and isatuximab against EL4 thymoma or VK*MYC myeloma cells overexpressing human CD38. These results highlight the preclinical efficacy of SAR442085 and support the current evaluation of this next-generation anti-CD38 antibody in phase I clinical development in patients with relapsed/refractory MM.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kassem S, Diallo BK, El-Murr N, et al. SAR442085, a novel anti-CD38 antibody with enhanced antitumor activity against multiple myeloma. Blood. 2022. PMID: 35201323. doi:10.1182/blood.2021012448

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。